EUVIMEDEUVIMED entdecken
Crossref

Design of Orally-bioavailable Tetra-cyclic phthalazine SOS1 inhibitors with high selectivity against EGFR

Huan He, Ruiqi Chen, Ziwei Wang, Luolong Qing, Yu Zhang, Yi Liu, Weidong Pan, Huaxiang Fang, Silong Zhang

Bioorganic Chemistry · 2023

DOI: 10.1016/j.bioorg.2023.106536 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Bioorganic Chemistry, 2023. Verfasst von Huan He und 8 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmaceutical Sciences, Guizhou University, Guiyang 550025, PR China; Key Laboratory of Coal Conversion and New Carbon Materials of Hubei …. Hauptthemen laut MEDLINE: SOS1 Protein, Proto-Oncogene Proteins p21(ras). Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 32 Literaturangaben. Gefördert von: Tianjin Science and Technology Committee, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

KRAS mutations (G12C, G12D, etc.) are implicated in the oncogenesis and progression of many deadliest cancers. Son of sevenless homolog 1 (SOS1) is a crucial regulator of KRAS to modulate KRAS from inactive to active states. We previously discovered tetra-cyclic quinazolines as an improved scaffold for inhibiting SOS1-KRAS interaction. In this work, we report the design of tetra-cyclic phthalazine derivatives for selectively inhibiting SOS1 against EGFR. The lead compound 6c displayed remarkable activity to inhibit the proliferation of KRAS(G12C)-mutant pancreas cells. 6c showed a favorable pharmacokinetic profile in vivo, with a bioavailability of 65.8% and exhibited potent tumor suppression in pancreas tumor xenograft models. These intriguing results suggested that 6c has the potential to be developed as a drug candidate for KRAS-driven tumors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SOS1 ProteinProto-Oncogene Proteins p21(ras)HumansMutationQuinazolinesErbB Receptors

Stichwörter der Autor:innen

EGFRKRASProtein–protein interactionSOS1Tetra-cyclic phthalazine

Substanzen

SOS1 ProteinProto-Oncogene Proteins p21(ras)QuinazolinesErbB ReceptorsEGFR protein, human

Autor:innen und Institutionen

  • School of Pharmaceutical Sciences, Guizhou University, Guiyang 550025, PR China; Key Laboratory of Coal Conversion and New Carbon Materials of Hubei Province, College of Chemistry and Chemical Engineering, Wuhan Univers…
  • Key Laboratory of Coal Conversion and New Carbon Materials of Hubei Province, College of Chemistry and Chemical Engineering, Wuhan University of Science and Technology, Wuhan 430081, PR China.
  • Key Laboratory of Coal Conversion and New Carbon Materials of Hubei Province, College of Chemistry and Chemical Engineering, Wuhan University of Science and Technology, Wuhan 430081, PR China; School of Chemical and Env…
  • School of Pharmaceutical Sciences, Guizhou University, Guiyang 550025, PR China. Electronic address: wdpan@163.com.
  • Key Laboratory of Coal Conversion and New Carbon Materials of Hubei Province, College of Chemistry and Chemical Engineering, Wuhan University of Science and Technology, Wuhan 430081, PR China. Electronic address: fang_h…

Förderung

  • Tianjin Science and Technology Committee
  • National Natural Science Foundation of China

Zitieren

APA

He, H., Chen, R., Wang, Z., Qing, L., Zhang, Y., Liu, Y., Pan, W., Fang, H., & Zhang, S. (2023). Design of Orally-bioavailable Tetra-cyclic phthalazine SOS1 inhibitors with high selectivity against EGFR. Bioorganic Chemistry. https://doi.org/10.1016/j.bioorg.2023.106536

Vancouver

He H, Chen R, Wang Z, Qing L, Zhang Y, Liu Y, et al. Design of Orally-bioavailable Tetra-cyclic phthalazine SOS1 inhibitors with high selectivity against EGFR. Bioorganic Chemistry. 2023. doi:10.1016/j.bioorg.2023.106536

BibTeX
@article{He2023,
  author = {He, Huan and Chen, Ruiqi and Wang, Ziwei and Qing, Luolong and Zhang, Yu and Liu, Yi and Pan, Weidong and Fang, Huaxiang and Zhang, Silong},
  title = {Design of Orally-bioavailable Tetra-cyclic phthalazine SOS1 inhibitors with high selectivity against EGFR},
  journal = {Bioorganic Chemistry},
  year = {2023},
  doi = {10.1016/j.bioorg.2023.106536}
}
Kostenlos starten →